J&J privately asked rival COVID-19 vaccine manufacturers to investigate clotting risks

<div id=”js-article__body” itemprop=”articleBody” data-sbid=”FBD1B320-9EAF-11EB-81D0-955AE1F48F8C”>

Johnson & Johnson privately reached out to Covid-19 vaccine rivals asking them to join an effort to study the risks of blood clots and speak with one voice about safety, but Pfizer Inc. and Moderna Inc. they refused. As concerns mounted last week about rare cases of blood clots, J&J US: JNJ asked AstraZeneca PLC US: AZN UK: AZN as well as Pfizer US: PFE and US: MRNA to join their efforts to investigate. the reports, people familiar with the said matter. J&J, through emails and phone calls, also sought to build an informal alliance to communicate the benefits and risks of vaccines and address any concerns raised among the public about blood clot cases, some of the people said.

Six women who received the J&J vaccine developed clots and one died, from more than seven million doses administered in the US, according to federal health officials. The specific adverse event has not been reported by people who received the Pfizer and Moderna injections, officials said. Executives at Pfizer and Moderna rejected the offer, saying their vaccines appeared safe, the people said. The couple also objected because they did not see a need to duplicate efforts by regulators and companies already looking for blood clots and investigating the cause, the people said. One company’s concern: The safety of Pfizer and Moderna injections could be tarnished by association, some of the people said. Only AstraZeneca, which had been hit by similar concerns about blood clotting for weeks, agreed, the people said. An expanded version of this report appears on WSJ.com. Most Popular on WSJ.com: Small group of COVID-19 infections seen in fully vaccinated patients. Chauvin decides not to testify about Floyd’s death.